We are proud to announce the latest impact factor for the British Society for Immunology’s official journal Clinical & Experimental Immunology (CEI), which has reached its highest-ever impact factor of 5.732.
We’d like to take this opportunity to celebrate CEI for building upon its position as a long-standing and highly-respected publication in the field of immunology. We’d like to thank the editorial team, led superbly by Editor-in-Chief Professor Leonie Taams, for their ongoing commitment to the journal, and everyone who has contributed to the continued success of CEI, including authors, readers, reviewers and editors.
Whilst we are aware that the impact factor has certain limitations, we take this as one measure of the high-quality work submitted by our authors.
We have curated a selection of impactful articles published in the journal to create a more comprehensive picture of research influence shown by various indicators, such as engagement and dissemination, which supplements citations. The High Impact Collection includes the top cited, most discussed (according to Altmetric scores), and top downloaded articles from 2020-present for you to read and enjoy.
We would also like to take this opportunity to highlight other successes from the BSI family of journals. We are continuing to achieve our goal of publishing content that is timely and relevant to our research community, as demonstrated by key metrics and milestones:
- Mean time to first decision: 19 days
- Mean time to final decision: 30 days
- 5-year impact factor: 5.163
- Immediacy index: 0.956
- Mean time to first decision: 34 days
- Mean time to final decision: 73 days
- Yearly usage: 54,191 full-text downloads
- Indexed in the Directory of Open Access Journals
- Published inaugural Editorial in January 2022
- First articles accepted are now online
- Started building an online community through our Twitter channel @discovimmunol
You can find more information about our journals here: Clinical & Experimental Immunology, Immunotherapy Advances and Discovery Immunology, We offer a broad suite of additional benefits to authors, including a very rapid time to first decision, live Altmetric tracking on your articles, no page or colour charges for members, integration with Publons, and the skills of a dedicated marketing team who will promote your article to interested parties.
Profits derived from the sale of the journals are invested back into the BSI to benefit our members in the form of grants, travel awards, BSI Regional and Affinity Group meetings, our popular BSI Congress and other key initiatives. We encourage you to support the BSI by submitting your work.